Get the Stockscreener App
2.71
1.45%
-0.04
Pre-market:
2.57
-0.14
-5.17%
Silexion Therapeutics Corp stock is traded at $2.71, with a volume of 306.35K.
It is down -1.45% in the last 24 hours and down -6.23% over the past month.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
See More
Previous Close:
$2.75
Open:
$2.51
24h Volume:
306.35K
Relative Volume:
0.53
Market Cap:
$2.88M
Revenue:
-
Net Income/Loss:
$-11.91M
P/E Ratio:
-0.3057
EPS:
-8.8661
Net Cash Flow:
$-10.83M
1W Performance:
-35.01%
1M Performance:
-6.23%
6M Performance:
-89.62%
1Y Performance:
-97.85%
1-Day Range:
$2.33
$2.775
1-Week Range:
$2.33
$3.98
52-Week Range:
$2.31
$223.60
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
2.71 | 2.92M | 0 | -11.91M | -10.83M | -8.8661 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
SLXN Q1 2026 Earnings: Narrowed Loss Beats Estimates with 35.4% EPS SurpriseAnalyst Drop Coverage - newsline.com
Silexion Therapeutics (NASDAQ: SLXN) registers up to 859,609 resale shares - Stock Titan
Silexion Therapeutics Warrants (SLXNW) Plunge 33% as Support at $0.03 Faces TestValue Factor - newsline.com
Silexion Therapeutics Corp Ord Stock Short Interest Falls to 43.76% - Quiver Quantitative
SLXN Q1 2026 Earnings: Narrowed Loss Per Share Surprises, Stock GainsCapex Guidance - newsline.com
Number of shareholders of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
Silexion (SLXN) awards CSO 6,000 RSUs after reverse share split - Stock Titan
[Form 4] Silexion Therapeutics Corp Insider Trading Activity - Stock Titan
Silexion (SLXN) CEO granted 10,000 shares; holdings rise to 16,547 - Stock Titan
Silexion Therapeutics Corp (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline ProgressesGross Profit Margin - newsline.com
Number of shareholders of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Silexion (SLXN) asks shareholders to OK 399,020 warrants and a capital increase - Stock Titan
Silexion Stock Just Split 1-for-10. The Real Test Starts Now - Bez Kabli
Silexion Therapeutics Implements 1-for-10 Reverse Share Split - The Globe and Mail
Moringa (SLXN) discloses 1,382,346-share Silexion stake and contests note issuances - Stock Titan
- newsline.com
Silexion Therapeutics Corp Files Form 8-K: NASDAQ Listing, Company Details, and Warrant Information - Minichart
Silexion Therapeutics (SLXN) completes 1-for-10 reverse split, adjusts warrant terms - Stock Titan
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplinePreliminary Results - thelegaladvocate.com
Silexion Therapeutics announces 1-for-10 reverse share split - MSN
Silexion Therapeutics (SLXN) Slips 3% as Shares Test Key Support at $0.40Shakeout Pattern - thelegaladvocate.com
Silexion Therapeutics Corp Warrant (SLXNW) Faces Continued Selling Pressure at Penny LevelRevenue Weighted - newsline.com
Silexion Therapeutics Announces Reverse Split to Maintain Listing - The Globe and Mail
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineWeak Earnings Momentum - newsline.com
Silexion Therapeutics Begins GMP Manufacturing of SIL204 and Receives Approval for Phase 2/3 Trial at Tel Aviv Sourasky Medical Center - geneonline.com
Silexion announces 1-for-10 reverse stock split effective Thursday By Investing.com - Investing.com Australia
Silexion Therapeutics Announces 1-For-10 Reverse Share Split - TradingView
Silexion announces 1-for-10 reverse stock split effective Thursday - Investing.com
Silexion Therapeutics to implement 1-for-10 reverse share split, effective May 29, 2026 - TradingView
Silexion (NASDAQ: SLXN) plans 1-for-10 reverse share split to aid Nasdaq compliance - Stock Titan
Silexion Therapeutics Announces 1-for-10 Reverse Share Split - Moomoo
Silexion Therapeutics Corp Warrant (SLXNW) Struggles Near $0.02: Low Volume and Narrow Trading RangeMutual Fund Flow - newsline.com
Silexion Therapeutics (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionCore Business Growth - newsline.com
Silexion Therapeutics (SLXN): Modest Gains as Stock Holds Key Support at $0.46Percent Above MA - Newser
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Surprise but Stock DeclinesFinal Results - newsline.com
Silexion Therapeutics prices new warrants exercise deal at $0.50 to raise $1M - MSN
Silexion Therapeutics Stock Surges 97% on Phase 2/3 Trial Approval - Meyka
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN - TechStock²
Silexion Therapeutics(SLXN) Stock Options Chain | Quotes & News - Moomoo
Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results - Investorideas.com
Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative
Silexion’s Cancer Trial Push Puts Focus on Cash - TechStock²
Silexion Therapeutics Posts Wider Q1 Loss, Advances SIL204 Into Phase 2/3 Trials; Stock Up - RTTNews
Silexion Therapeutics (SLXN) Gained +56.13% — Can It Break $0.44? 2026-05-20MAMA Signal - Newser
Silexion (NASDAQ: SLXN) 10-K amendment corrects internal control date - Stock Titan
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):